Kura Oncology (KURA) Leases (2019 - 2026)

Kura Oncology (KURA) has 8 years of Leases data on file, last reported at $7.2 million in Q1 2026.

• Quarterly Leases fell 11.95% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 11.95% YoY) and the FY2025 annual result came in at $7.3 million, up 25.83% from the prior year.
• Leases retreated to $7.2 million in Q1 2026 per KURA's latest filing, from $7.3 million in the prior quarter.
• Across five years, Leases topped out at $8.1 million in Q1 2025 and bottomed at $2.9 million in Q2 2023.
• The 5-year median for Leases is $6.4 million (2024), against an average of $6.0 million.
• The widest annual swing landed in 2023, when Leases slumped 37.85%; it then surged 118.21% in 2024.
• Tracing KURA's Leases over 5 years: stood at $3.8 million in 2022, then soared by 82.01% to $7.0 million in 2023, then retreated by 17.02% to $5.8 million in 2024, then advanced by 25.83% to $7.3 million in 2025, then retreated by 1.86% to $7.2 million in 2026.
• Per Business Quant, the three latest KURA Leases figures stand at $7.2 million (Q1 2026), $7.3 million (Q4 2025), and $7.5 million (Q3 2025).

Peer Comparison